1. Home
  2. DGII vs SNDX Comparison

DGII vs SNDX Comparison

Compare DGII & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digi International Inc.

DGII

Digi International Inc.

HOLD

Current Price

$44.15

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$21.04

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DGII
SNDX
Founded
1985
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
DGII
SNDX
Price
$44.15
$21.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
12
Target Price
$46.80
$36.92
AVG Volume (30 Days)
295.4K
1.6M
Earning Date
02-04-2026
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
77.05
N/A
EPS
1.08
N/A
Revenue
$430,221,000.00
$111,304,000.00
Revenue This Year
$10.51
$620.14
Revenue Next Year
$8.01
$115.42
P/E Ratio
$41.19
N/A
Revenue Growth
1.46
595.65
52 Week Low
$22.39
$8.58
52 Week High
$48.00
$22.73

Technical Indicators

Market Signals
Indicator
DGII
SNDX
Relative Strength Index (RSI) 56.44 61.35
Support Level $43.60 $19.72
Resistance Level $44.59 $22.73
Average True Range (ATR) 1.23 0.88
MACD -0.34 -0.08
Stochastic Oscillator 18.64 52.21

Price Performance

Historical Comparison
DGII
SNDX

About DGII Digi International Inc.

Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: